Open access
Open access
Powered by Google Translator Translator

Retrospective Cohort Study: Incidence of major adverse cardiac events with immune checkpoint inhibitors.

13 Jun, 2022 | 07:32h | UTC

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program – Journal of Clinical Oncology

Related:

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment – Journal of the American Heart Association

Cardiotoxicity of immune checkpoint inhibitors – ESMO Open

Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.